Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105900183 | 10590018 | 3 | F | 20140920 | 20160815 | 20141118 | 20160822 | EXP | US-PFIZER INC-2014313090 | PFIZER | 53.00 | YR | F | Y | 125.00000 | KG | 20160822 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105900183 | 10590018 | 1 | SS | BOCOCIZUMAB | BOCOCIZUMAB | 1 | Subcutaneous | 150 MG, EVERY 2 WEEKS | 0 | 150 | MG | SOLUTION FOR INJECTION | |||||||
| 105900183 | 10590018 | 2 | PS | LYRICA | PREGABALIN | 1 | Oral | 100 MG, 3X/DAY | 21446 | 100 | MG | TID | |||||||
| 105900183 | 10590018 | 3 | SS | LASIX | FUROSEMIDE | 1 | Oral | 80 MG, 1X/DAY | 0 | 80 | MG | QD | |||||||
| 105900183 | 10590018 | 4 | C | HUMALOG | INSULIN LISPRO | 1 | UNK | 0 | |||||||||||
| 105900183 | 10590018 | 5 | C | VICTOZA | LIRAGLUTIDE | 1 | UNK | 0 | |||||||||||
| 105900183 | 10590018 | 6 | C | LISINOPRIL. | LISINOPRIL | 1 | UNK | 0 | |||||||||||
| 105900183 | 10590018 | 7 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | UNK | 0 | |||||||||||
| 105900183 | 10590018 | 8 | C | PRADAXA | DABIGATRAN ETEXILATE MESYLATE | 1 | UNK | 0 | |||||||||||
| 105900183 | 10590018 | 9 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | UNK | 0 | |||||||||||
| 105900183 | 10590018 | 10 | C | CYCLOBENZAPRINE | CYCLOBENZAPRINE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 105900183 | 10590018 | 1 | Hyperlipidaemia |
| 105900183 | 10590018 | 2 | Neuropathy peripheral |
| 105900183 | 10590018 | 3 | Cardiac failure congestive |
| 105900183 | 10590018 | 4 | Type 2 diabetes mellitus |
| 105900183 | 10590018 | 5 | Type 2 diabetes mellitus |
| 105900183 | 10590018 | 6 | Hypertension |
| 105900183 | 10590018 | 7 | Hyperlipidaemia |
| 105900183 | 10590018 | 8 | Atrial fibrillation |
| 105900183 | 10590018 | 9 | Gastrooesophageal reflux disease |
| 105900183 | 10590018 | 10 | Muscle spasms |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 105900183 | 10590018 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 105900183 | 10590018 | Cardiac failure congestive | |
| 105900183 | 10590018 | Condition aggravated |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 105900183 | 10590018 | 1 | 20140902 | 20150512 | 0 | |
| 105900183 | 10590018 | 2 | 2011 | 0 | ||
| 105900183 | 10590018 | 3 | 2011 | 0 |